282 related articles for article (PubMed ID: 21121856)
1. Paroxysmal nocturnal hemoglobinuria--hemolysis before and after eculizumab.
Risitano AM; Notaro R; Luzzatto L; Hill A; Kelly R; Hillmen P
N Engl J Med; 2010 Dec; 363(23):2270-2. PubMed ID: 21121856
[No Abstract] [Full Text] [Related]
2. Hemolytic anemia after eculizumab in paroxysmal nocturnal hemoglobinuria.
Berzuini A; Montanelli F; Prati D
N Engl J Med; 2010 Sep; 363(10):993-4. PubMed ID: 20818912
[No Abstract] [Full Text] [Related]
3. Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization.
Hill A; Rother RP; Arnold L; Kelly R; Cullen MJ; Richards SJ; Hillmen P
Haematologica; 2010 Apr; 95(4):567-73. PubMed ID: 20145265
[TBL] [Abstract][Full Text] [Related]
4. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Yuan X; Gavriilaki E; Thanassi JA; Yang G; Baines AC; Podos SD; Huang Y; Huang M; Brodsky RA
Haematologica; 2017 Mar; 102(3):466-475. PubMed ID: 27810992
[TBL] [Abstract][Full Text] [Related]
5. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.
Hillmen P; Hall C; Marsh JC; Elebute M; Bombara MP; Petro BE; Cullen MJ; Richards SJ; Rollins SA; Mojcik CF; Rother RP
N Engl J Med; 2004 Feb; 350(6):552-9. PubMed ID: 14762182
[TBL] [Abstract][Full Text] [Related]
6. Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3.
Risitano AM; Perna F; Selleri C
Mini Rev Med Chem; 2011 Jun; 11(6):528-35. PubMed ID: 21561403
[TBL] [Abstract][Full Text] [Related]
7. C3-mediated extravascular hemolysis in PNH on eculizumab: Mechanism and clinical implications.
Notaro R; Sica M
Semin Hematol; 2018 Jul; 55(3):130-135. PubMed ID: 30032749
[TBL] [Abstract][Full Text] [Related]
8. Extravascular hemolytic attack after eculizumab therapy for paroxysmal nocturnal hemoglobinuria.
Tomita A; Shirasugi Y; Ito T; Tsurumi H; Naoe T
Ann Hematol; 2012 Jul; 91(7):1139-41. PubMed ID: 22080148
[No Abstract] [Full Text] [Related]
9. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
Hillmen P; Young NS; Schubert J; Brodsky RA; Socié G; Muus P; Röth A; Szer J; Elebute MO; Nakamura R; Browne P; Risitano AM; Hill A; Schrezenmeier H; Fu CL; Maciejewski J; Rollins SA; Mojcik CF; Rother RP; Luzzatto L
N Engl J Med; 2006 Sep; 355(12):1233-43. PubMed ID: 16990386
[TBL] [Abstract][Full Text] [Related]
10. New insights into paroxysmal nocturnal hemoglobinuria.
Savage WJ; Brodsky RA
Hematology; 2007 Oct; 12(5):371-6. PubMed ID: 17852463
[TBL] [Abstract][Full Text] [Related]
11. Improvement in the symptoms of smooth muscle dystonia during eculizumab therapy in paroxysmal nocturnal hemoglobinuria.
Hill A; Rother RP; Hillmen P
Haematologica; 2005 Dec; 90(12 Suppl):ECR40. PubMed ID: 16464755
[TBL] [Abstract][Full Text] [Related]
12. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab.
Risitano AM; Notaro R; Marando L; Serio B; Ranaldi D; Seneca E; Ricci P; Alfinito F; Camera A; Gianfaldoni G; Amendola A; Boschetti C; Di Bona E; Fratellanza G; Barbano F; Rodeghiero F; Zanella A; Iori AP; Selleri C; Luzzatto L; Rotoli B
Blood; 2009 Apr; 113(17):4094-100. PubMed ID: 19179465
[TBL] [Abstract][Full Text] [Related]
13. Failure of eculizumab to correct paroxysmal cold hemoglobinuria.
Gregory GP; Opat S; Quach H; Shortt J; Tran H
Ann Hematol; 2011 Aug; 90(8):989-90. PubMed ID: 21110191
[No Abstract] [Full Text] [Related]
14. Update on eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
Hill A
Clin Adv Hematol Oncol; 2008 Jul; 6(7):499-500. PubMed ID: 18654116
[No Abstract] [Full Text] [Related]
15. A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement.
Lindorfer MA; Pawluczkowycz AW; Peek EM; Hickman K; Taylor RP; Parker CJ
Blood; 2010 Mar; 115(11):2283-91. PubMed ID: 20068220
[TBL] [Abstract][Full Text] [Related]
16. Eculizumab: a guide to its use in paroxysmal nocturnal hemoglobinuria.
Keating GM; Lyseng-Williamson KA; McKeage K
BioDrugs; 2012 Apr; 26(2):125-30. PubMed ID: 22350448
[TBL] [Abstract][Full Text] [Related]
17. Successful use of eculizumab in a pediatric patient treated for paroxysmal nocturnal hemoglobinuria.
Bauters T; Bordon V; Robays H; Benoit Y; Dhooge C
J Pediatr Hematol Oncol; 2012 Nov; 34(8):e346-8. PubMed ID: 22767128
[TBL] [Abstract][Full Text] [Related]
18. Perisurgical induction of eculizumab in a patient with paroxysmal nocturnal hemoglobinuria: its inhibition of surgery-triggered hemolysis and the consequence of subsequent discontinuation.
Kurita N; Obara N; Fukuda K; Nishikii H; Sato S; Inagawa S; Kurokawa T; Owada Y; Ninomiya H; Chiba S
Blood Coagul Fibrinolysis; 2013 Sep; 24(6):658-62. PubMed ID: 23917586
[TBL] [Abstract][Full Text] [Related]
19. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria.
Hillmen P; Elebute M; Kelly R; Urbano-Ispizua A; Hill A; Rother RP; Khursigara G; Fu CL; Omine M; Browne P; Rosse W
Am J Hematol; 2010 Aug; 85(8):553-9. PubMed ID: 20658586
[TBL] [Abstract][Full Text] [Related]
20. Life-threatening desquamating rash and hyperammonemia following administration of eculizumab for paroxysmal nocturnal hemoglobinuria.
Knoll BM; Letendre L; Steensma DP
Am J Hematol; 2008 Nov; 83(11):881-3. PubMed ID: 18756538
[No Abstract] [Full Text] [Related]
[Next] [New Search]
